Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

BP-C2 mitigates radiation-induced gastrointestinal syndrome in mice

Oct. 16, 2020

Selective PDEB inhibitor shows promising preclinical results for the treatment of cocaine addiction

Oct. 9, 2020

Sobrera and Recipharm collaborate on formulation development of SO-001 for alcohol use disorder

Sep. 29, 2020

Microglial pruning under the influence links alcohol to anxiety

Sep. 28, 2020

Proniras receives NIDA grant to pursue development of tezampanel for opioid withdrawal

Sep. 18, 2020

Embera begins phase II study of EMB-001 for cocaine use disorder

Sep. 1, 2020

FDA clears IND for phase II study of TNX-102 SL

Aug. 7, 2020

Indivior begins first-in-human study of INDV-2000 for opioid dependence

July 9, 2020

Idorsia Pharmaceuticals identifies new Ox1-R and Ox2-R antagonists

June 4, 2020

Estrogen and dopamine

June 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...